直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

“2” Does Not Provide Written Description Support for “1”: Federal Circuit Affirms District Court’s Invalidation of Patent

July 8, 2026

Authored and Edited by Wyatt L. Bazrod; Erik R. Puknys; *Emma Cagwin

In Enanta Pharms., Inc. v. Pfizer Inc., No. 25-1427, (Fed. Cir. June 23, 2026), the Federal Circuit affirmed the district court’s grant of summary judgment invalidating U.S. Patent No. 11,358,953 (“the ’953 patent”).

The ’953 patent issued from a nonprovisional application filed on November 9, 2021, and claims priority to U.S. Provisional Patent App. No. 63/054,048 (“the ’048 provisional”) with a priority date of July 20, 2020. Notably, the ’048 provisional discloses a two-to-twelve alkyl group (“C2-C12-alkyl”) whereas the ’953 patent discloses a one-to-twelve alkyl group (“C1-C12-alkyl”). Between the filing of the ’048 provisional and the ’953 patent, Pfizer publicly disclosed an inhibitor with a C1-alkyl structure.

Enanta sued Pfizer, alleging that Pfizer’s Paxlovid® product, a coronavirus treatment, infringed the ’953 patent. On summary judgment, Pfizer argued that the ’953 patent was invalid because there was no written description support for the C1-alkyl structure in the ’048 provisional, and thus, Pfizer’s intervening public disclosure anticipated the ’953 patent claims.

Enanta agreed that the claims would be anticipated if the priority claim failed, but argued the Court could should correct what it characterized as a typographical error in the ’048 provisional. The district court disagreed and granted summary judgment for Pfizer.

The Federal Circuit explained that the issue turned on whether the ’048 provisional provided adequate written description support for the claimed C1-alkyl substituent. Enanta argued an inconsistency in the ’048 provisional’s definition of “alkyl” purportedly showed that references to “C2-C12-alkyl” were typographical errors that should have been read as “C1-C12-alkyl.” The Court disagreed, concluding that an alleged error elsewhere in the specification did not create a factual dispute that the specific disclosure of the C2-C12-alkyl group was mistaken.

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Related Industries

Life Sciences

Pharmaceutical

Related Offices

Atlanta, GA

Washington, DC

Contacts

Wyatt L. Bazrod
Associate
Atlanta, GA
+1 404 653 6518
Email
Erik R. Puknys
Partner
Palo Alto, CA
+1 650 849 6644
Email

*Emma Cagwin is a Summer Associate at Finnegan.

Copyright © Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information. 

Related Insights

Conference

2027 ABA-IPL Section Annual Meeting – IPLSPRING

April 14-15, 2027

Arlington

Conference

IAM Live: IPBC Europe 2027

March 15-17, 2026

Istanbul

Conference

Patent Litigation Europe 2027

January 18-20, 2027

Amsterdam

Reception

2026 IPO Education Foundation Awards Dinner

December 15, 2026

Washington, DC

Seminar

Global Innovation Index: Perspectives on IP and Innovation Ecosystems

December 14, 2026

Washington, DC

Conference

IP Life Sciences Forum 2026

December 13-15, 2026

Coral Gables

Seminar

Global Patent Strategies for Life Sciences and Chemical Innovations: Key Developments in Europe and the United States – Osaka

December 10, 2026

Osaka

Webinar

Trade Secret Laws and Sausages: A Look at Efforts to Update the UTSA

December 10, 2026

Webinar

Seminar

Global Patent Strategies for Life Sciences and Chemical Innovations: Key Developments in Europe and the United States – Tokyo

December 8, 2026

Tokyo

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP